StockTitan

@stocktitan.net

16 hours ago

Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA™ (bevacizumab-vikg) Accepted by FDA Outlook Therapeutics (Nasdaq: OTLK) announced that the FDA accepted its Formal Dispute Resolution Request (FDRR) for ONS-5010/LYTENAVA™ (bevacizumab-vikg) and granted a meeting with the deciding official in April 2026. The FDRR follows a December 30, 2025 Complete Response Letter and a March 2, 2026 Type A meeting.Outlook cites Phase 3 NORSE TWO and NORSE EIGHT data that it says support efficacy and safety; the company reports no FDA safety concerns and notes a U.S. end-to-end manufacturing supply chain.

#OTLK #OTLKW Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA™ (bevacizumab-vikg) Accepted by FDA

www.stocktitan.net/news/OTLK/outlook-therap...

StockTitan

@stocktitan.net

2 weeks ago

Outlook Therapeutics Announces Pricing of $5.0 Million Public Offering Outlook Therapeutics (Nasdaq: OTLK) priced a public offering of 20,000,000 shares and accompanying warrants to buy 20,000,000 shares at a combined price of $0.25 per share/warrant, yielding aggregate gross proceeds of $5.0 million before fees.Each warrant is exercisable immediately at $0.25 and expires five years from issuance; the offering is expected to close on or about March 25, 2026.

#OTLK #OTLKW Outlook Therapeutics Announces Pricing of $5.0 Million Public Offering

www.stocktitan.net/news/OTLK/outlook-therap...

StockTitan

@stocktitan.net

2 weeks ago

Outlook Therapeutics Announces Proposed Public Offering Outlook Therapeutics (Nasdaq: OTLK) announced on March 23, 2026 that it has commenced a best-efforts public offering of common stock (or pre-funded warrants) and accompanying warrants exercisable for common stock. The offering is subject to market and other conditions and may not be completed.H.C. Wainwright is the exclusive placement agent. Net proceeds are intended primarily for working capital and general corporate purposes. The securities are offered under an effective Form S-3 shelf registration (File No. 333-278340); a prospectus supplement will be filed with the SEC.

#OTLK #OTLKW Outlook Therapeutics Announces Proposed Public Offering

www.stocktitan.net/news/OTLK/outlook-therap...

StockTitan

@stocktitan.net

1 month ago

Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg) Outlook Therapeutics (Nasdaq: OTLK) provided a regulatory update after a Type A meeting with the U.S. FDA regarding the Dec 30, 2025 Complete Response Letter for its BLA for ONS-5010/LYTENAVA (bevacizumab-vikg). The meeting focused on the FDA’s outstanding substantial-evidence issue and potential paths to approval.NORSE TWO met its primary and key secondary endpoints with clinically meaningful, statistically significant visual-acuity improvements; NORSE EIGHT and other data were submitted as confirmatory evidence. The FDA identified no safety concerns. The company is evaluating regulatory options and continuing discussions to clarify confirmatory evidence and next steps toward potential U.S. approval.

#OTLK #OTLKW Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg)

www.stocktitan.net/news/OTLK/outlook-therap...

StockTitan

@stocktitan.net

3 months ago

Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD Outlook Therapeutics (Nasdaq: OTLK) said the U.S. Food and Drug Administration issued a Complete Response Letter (CRL) for the resubmitted biologics license application for ONS-5010/LYTENAVA (bevacizumab-vikg) for wet age-related macular degeneration (wet AMD), indicating the application cannot be approved in its present form.The FDA noted one adequate and well-controlled study demonstrated efficacy but again requested confirmatory evidence of efficacy and did not specify what evidence would be acceptable. The resubmission was based on the NORSE clinical program (including NORSE TWO and NORSE EIGHT).Outlook said it is exploring U.S. approval pathways and continuing commercial expansion in Europe, where LYTENAVA received European Commission and MHRA marketing authorizations and became commercially available in Germany and the UK in June 2025.

#OTLK #OTLKW Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD

www.stocktitan.net/news/OTLK/outlook-therap...

StockTitan

@stocktitan.net

3 months ago

Outlook Therapeutics Reports Financial Results for Fiscal Year 2025 Outlook Therapeutics (Nasdaq: OTLK) reported fiscal 2025 results for the year ended September 30, 2025. The company recorded a net loss of $62.4 million ($1.79 per share) and $1.4 million of revenue from initial European sales of LYTENAVA in June 2025. Gross profit was reduced by increased reserves for short-dated inventory from UK shipments. Operating expenses fell year-over-year driven by lower R&D after completion of NORSE Eight, offset by higher SG&A from the European launch. Cash and equivalents were $8.1 million at September 30, 2025, plus $14.9 million net ATM proceeds received after the period. The FDA PDUFA goal date for ONS-5010 is December 31, 2025.

#OTLK #OTLKW Outlook Therapeutics Reports Financial Results for Fiscal Year 2025

www.stocktitan.net/news/OTLK/outlook-therap...

StockTitan

@stocktitan.net

4 months ago

Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today

#OTLK #OTLKW Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

www.stocktitan.net/news/OTLK/outlook-therap...

StockTitan

@stocktitan.net

5 months ago

Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010 Outlook Therapeutics (Nasdaq: OTLK) re-submitted its Biologics License Application (BLA) for ONS-5010 to the U.S. FDA on Nov 3, 2025 after receiving official minutes from an FDA Type A meeting held in September 2025. ONS-5010 is an investigational ophthalmic bevacizumab formulation proposed to be branded LYTENAVA™ (bevacizumab-vikg) for the treatment of wet age-related macular degeneration (wet AMD).The company said the resubmission is intended to resolve the outstanding issue identified in a Complete Response Letter (CRL) dated August 2025 and that it is accelerating commercial efforts in Europe while positioning for a potential near-term U.S. approval.

#OTLK #OTLKW Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010

www.stocktitan.net/news/OTLK/outlook-therap...

StockTitan

@stocktitan.net

7 months ago

FDA Requests Additional Efficacy Data: Outlook Therapeutics Plans Meeting on Wet-AMD Drug ONS-5010 Biotech firm seeks FDA Type A meeting following complete response letter for ONS-5010 bevacizumab formulation. NORSE TWO trial met endpoints, but FDA requests confirmatory efficacy data.

#OTLK #OTLKW Outlook Therapeutics Requests Type A Meeting with FDA

www.stocktitan.net/news/OTLK/outlook-therap...

StockTitan

@stocktitan.net

7 months ago

Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD Outlook Therapeutics (NASDAQ: OTLK) announced that the FDA has issued a Complete Response Letter (CRL) for ONS-5010/LYTENAVA™ (bevacizumab-vikg), their wet AMD treatment candidate. The FDA cannot approve the application in its current form due to lack of substantial evidence of effectiveness.The CRL highlighted that while the NORSE TWO trial met its primary endpoint, the NORSE EIGHT trial did not, leading to the FDA's recommendation for additional confirmatory efficacy evidence. Despite this setback in the U.S., LYTENAVA™ has already received Marketing Authorization in the European Union and UK, and has been commercially available in Germany and UK since June 2025 as the first authorized ophthalmic formulation of bevacizumab for wet AMD treatment.

#OTLK #OTLKW Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD

www.stocktitan.net/news/OTLK/outlook-therap...

StockTitan

@stocktitan.net

7 months ago

Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate Update Outlook Therapeutics (NASDAQ: OTLK) reported its Q3 FY2025 financial results and achieved significant milestones. The company recorded its first commercial sales of LYTENAVA™ (bevacizumab gamma) in Europe, marking its transition to a commercial-stage company. For Q3, OTLK reported revenue of $1.5 million and a net loss of $20.2 million ($0.55 per share).The company has a crucial PDUFA date of August 27, 2025, for ONS-5010/LYTENAVA™ FDA approval in the United States. LYTENAVA™ is now commercially available in Germany and UK for wet AMD treatment, with first patients already dosed. The company ended the quarter with cash and equivalents of $8.9 million.

#OTLK #OTLKW Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate Update

www.stocktitan.net/news/OTLK/outlook-therap...

StockTitan

@stocktitan.net

8 months ago

Exclusive: Outlook Therapeutics' New CEO Bob Jahr Reveals Growth Strategy for Retina Disease Treatment Watch new CEO Bob Jahr discuss Outlook Therapeutics' future in bevacizumab treatment for retina diseases. Access exclusive investor conference insights now.

#OTLK #OTLKW Outlook Therapeutics Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference

www.stocktitan.net/news/OTLK/outlook-therap...

StockTitan

@stocktitan.net

9 months ago

Breakthrough: Scotland NHS Approves First-Ever Licensed Bevacizumab Treatment for Wet AMD Patients First licensed ophthalmic bevacizumab secures 10-year UK market exclusivity. NHS Scotland patients gain access to new wet AMD treatment option. Learn more.

#OTLK #OTLKW Outlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

www.stocktitan.net/news/OTLK/outlook-therap...

StockTitan

@stocktitan.net

10 months ago

Breakthrough Eye Treatment: First-Ever Approved Bevacizumab for Wet AMD Now Available in Germany and UK LYTENAVA targets 2.8M annual European injections market. First approved ophthalmic bevacizumab for wet AMD launches in Germany/UK. See launch details.

#OTLK #OTLKW Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD

www.stocktitan.net/news/OTLK/outlook-therap...

StockTitan

@stocktitan.net

10 months ago

Outlook Therapeutics Secures $13M Financing: Key Details of Share Offering and Double Warrant Coverage Fresh capital raise includes warrants with 2:1 coverage at $1.40 strike price. Proceeds targeted for working capital needs. See complete offering terms.

#OTLK #OTLKW Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering

www.stocktitan.net/news/OTLK/outlook-therap...

StockTitan

@stocktitan.net

10 months ago

Outlook Therapeutics® Announces Proposed Public Offering of Common Stock and Warrants Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has commenced an underwritten public offering of its common

#OTLK #OTLKW Outlook Therapeutics® Announces Proposed Public Offering of Common Stock and Warrants

www.stocktitan.net/news/OTLK/outlook-therap...

StockTitan

@stocktitan.net

10 months ago

Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate Update Outlook Therapeutics (OTLK) reported its Q2 FY2025 financial results and provided key updates. The company is preparing for the commercial launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK in Q2 CY2025, following Marketing Authorization approvals in both regions. In the US, OTLK awaits FDA decision for ONS-5010 with a PDUFA date of August 27, 2025. The company reported a net loss of $46.4 million ($1.50 per share) and had cash reserves of $7.6 million as of March 31, 2025. LYTENAVA™ is positioned as the first authorized ophthalmic formulation of bevacizumab for wet AMD treatment, targeting a market where approximately 2.8 million off-label injections are administered annually in Europe and 2.7 million in the US. The company has partnered with Cencora for global commercial distribution.

#OTLK #OTLKW Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate Update

www.stocktitan.net/news/OTLK/outlook-therap...

StockTitan

@stocktitan.net

11 months ago

Major FDA Milestone: Novel Wet AMD Drug Gets Review Date, Could Be First-of-its-Kind Approval FDA sets August 2025 review date for potentially first-approved ophthalmic bevacizumab. Already approved in EU/UK. See market impact analysis inside.

#OTLK #OTLKW Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

www.stocktitan.net/news/OTLK/outlook-therap...

StockTitan

@stocktitan.net

1 year ago

Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration Outlook Therapeutics (OTLK) has re-submitted its Biologics License Application (BLA) to the FDA for ONS-5010, branded as LYTENAVA™ (bevacizumab-vikg), for treating wet age-related macular degeneration (wet AMD). The resubmission follows the company's recent regulatory approvals in the EU and UK.The BLA includes data from the NORSE EIGHT trial, a randomized study of 400 wet AMD patients comparing ONS-5010 to ranibizumab. While ONS-5010 showed clinical improvements with 3.3 to 5.5 letter improvement in vision across timepoints, it did not meet the pre-specified non-inferiority endpoint at week 8. However, anatomical response was comparable between treatments, with ONS-5010 achieving a -123.9 micron reduction in central retinal thickness versus -127.3 microns for ranibizumab.An FDA decision is expected within six months.

#OTLK #OTLKW Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration

www.stocktitan.net/news/OTLK/outlook-therap...

StockTitan

@stocktitan.net

1 year ago

Can This First-Ever Approved Ophthalmic Bevacizumab Transform Eye Treatment in 2025? First authorized ophthalmic bevacizumab developer presents strategic vision following European regulatory approvals for wet AMD treatment.

#OTLK #OTLKW Outlook Therapeutics® Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

www.stocktitan.net/news/OTLK/outlook-therap...

StockTitan

@stocktitan.net

1 year ago

Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update Outlook Therapeutics (OTLK) reported financial results for Q1 FY2025 and provided key updates. The company plans to resubmit its ONS-5010 BLA in Q1 2025, with potential FDA approval expected in Q3 2025. Commercial launches of LYTENAVA™ (bevacizumab gamma) are planned for Germany and UK in Q2 2025, marking the first authorized ophthalmic formulation of bevacizumab for wet AMD treatment in these regions.For Q1 FY2025, OTLK reported net income of $17.4 million ($0.72 per share), compared to a net loss of $11.2 million ($0.86 per share) in the same period last year. The company had cash and cash equivalents of $5.7 million as of December 31, 2024, with additional $17.8 million received in January 2025 from warrant exercises.In the NORSE EIGHT trial, while ONS-5010 missed the primary endpoint at week 8, it met non-inferiority margins at week 12, showing mean visual acuity improvements and similar anatomical response compared to ranibizumab.

#OTLK #OTLKW Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update

www.stocktitan.net/news/OTLK/outlook-therap...

StockTitan

@stocktitan.net

1 year ago

Major Clinical Trial Success: Revolutionary Eye Treatment Shows Promise in NORSE EIGHT Study Outlook Therapeutics shares complete safety and efficacy data from NORSE EIGHT trial for ONS-5010, their EU-approved wet AMD treatment, ahead of 2025 FDA submission.

#OTLK #OTLKW Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment

www.stocktitan.net/news/OTLK/outlook-therap...

StockTitan

@stocktitan.net

1 year ago

Outlook Therapeutics' ONS-5010 Matches Ranibizumab in 12-Week AMD Trial Results Outlook Therapeutics reports ONS-5010 achieved non-inferiority to ranibizumab at week 12 in wet AMD trial. Plans EU launch in 2025 following recent marketing approval.

#OTLK #OTLKW Outlook Therapeutics® Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial

www.stocktitan.net/news/OTLK/outlook-therap...

StockTitan

@stocktitan.net

1 year ago

Outlook's LYTENAVA Makes History: First Approved Ophthalmic Bevacizumab for Wet AMD in UK Outlook Therapeutics secures NICE recommendation for LYTENAVA, marking a breakthrough as the only authorized ophthalmic bevacizumab for wet AMD with 10-year EU/UK exclusivity.

#OTLK #OTLKW Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment

www.stocktitan.net/news/OTLK/outlook-therap...

StockTitan

@stocktitan.net

1 year ago

Outlook Therapeutics Secures EU Approval for LYTENAVA™, First Bevacizumab Eye Treatment for Wet AMD Outlook Therapeutics advances with EU/UK approval for LYTENAVA™, its pioneering wet AMD treatment. Plans 2025 launch amid expanding regulatory milestones, despite widening losses.

#OTLK #OTLKW Outlook Therapeutics® Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

www.stocktitan.net/news/OTLK/outlook-therap...

StockTitan

@stocktitan.net

1 year ago

Outlook Therapeutics Cuts 23% of Workforce Following EU Approval of Key Eye Treatment LYTENAVA Outlook Therapeutics streamlines operations amid mixed developments: workforce reduction for $1.4M savings, EU approval success, and planned FDA resubmission for wet AMD treatment.

#OTLK #OTLKW Outlook Therapeutics® Streamlines Operations

www.stocktitan.net/news/OTLK/outlook-therap...

StockTitan

@stocktitan.net

1 year ago

Outlook Therapeutics' LYTENAVA Secures Groundbreaking NICE Recommendation for Wet AMD Treatment | OTLK Stock News Outlook Therapeutics achieves first global reimbursement win for LYTENAVA in wet AMD treatment, targeting 40,000 UK patients with exclusive ophthalmic formulation.

#OTLK #OTLKW Outlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

#stocks #StockMarket #news

www.stocktitan.net/news/OTLK/outlook-therap...

StockTitan

@stocktitan.net

1 year ago

#OTLK #OTLKW Outlook Therapeutics® Announces Preliminary Topline Results of NORSE EIGHT Clinical Trial

www.stocktitan.net/news/OTLK/outlook-therap...